- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.01. | Xilio Therapeutics secures $35.8 million from warrant exercises | 1 | Investing.com | ||
| 08.01. | Xilio Therapeutics, Inc.: Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates | 953 | GlobeNewswire (Europe) | Received $35.8 million in gross proceeds from Series B warrant exercises, including full exercise by Coastlands Capital, Frazier Life Sciences and Gilead Sciences, Inc., and extended anticipated cash... ► Artikel lesen | |
| 05.01. | Xilio Therapeutics erzielt 35,8 Millionen US-Dollar aus Ausübung von Optionsscheinen | 2 | Investing.com Deutsch | ||
| 05.01. | Xilio Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 25.11.25 | Xilio Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| XILIO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 25.11.25 | Xilio Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.11.25 | Xilio Therapeutics GAAP EPS of -$0.11 misses by $0.08, revenue of $19.07M beats by $0.43M | 2 | Seeking Alpha | ||
| 13.11.25 | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results | 2.203 | GlobeNewswire (Europe) | Reported late-breaking Phase 2 data at SITC for vilastobart demonstrating a 40% ORR in heavily pretreated patients with MSS mCRC without liver metastases and high plasma tumor mutational burden Presented... ► Artikel lesen | |
| 13.11.25 | Xilio Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.11.25 | Xilio presents promising data for tumor-activated immunotherapies | 5 | Investing.com | ||
| 07.11.25 | Xilio reports 40% response rate in colorectal cancer treatment study | 2 | Investing.com | ||
| 07.11.25 | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual ... | 908 | GlobeNewswire (Europe) | 40% ORR in heavily pre-treated patients with MSS mCRC without liver metastases and with high plasma tumor mutational burden (TMB) Estimate 55% of patients with MSS CRC have high plasma TMB, representing... ► Artikel lesen | |
| 07.11.25 | Xilio Therapeutics, Inc.: Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting | 3 | GlobeNewswire (USA) | ||
| 07.11.25 | Xilio Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.11.25 | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 5 | GlobeNewswire (USA) | ||
| 30.10.25 | Xilio to present vilastobart phase 2 data at SITC annual meeting | 1 | Investing.com | ||
| 30.10.25 | Xilio Therapeutics, Inc.: Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 03.10.25 | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting | 2 | GlobeNewswire (USA) | ||
| 03.10.25 | Xilio Therapeutics wechselt am Montag an den Nasdaq Capital Market | 2 | Investing.com Deutsch | ||
| 03.10.25 | Xilio Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings |
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 309,11 | 0,00 % | H.C. Wainwright raises Praxis Precision Medicines stock price target to $1,245 | ||
| COGENT BIOSCIENCES | 37,960 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST) | - Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 26... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,74 | +0,23 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 25,650 | -0,27 % | Olema Oncology Announces Departure of Chief Operating and Financial Officer | SAN FRANCISCO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema", or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,060 | -2,77 % | H.C. Wainwright reiterates Buy rating on Summit Therapeutics stock | ||
| ARCELLX | 69,47 | 0,00 % | Arcellx präsentiert Daten zu Anito-Cel auf den Tandem Meetings 2026 | ||
| ARCUTIS BIOTHERAPEUTICS | 25,570 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis | 58% of participants achieved a 75% improvement in Eczema Area and Severity Index (EASI-75) with ZORYVE cream 0.05% at Week 4Investigational ZORYVE cream 0.05% was well tolerated and demonstrated a... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 75,62 | +4,03 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader | Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 65,93 | +2,15 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| QIAGEN | 44,060 | 0,00 % | Qiagen beruft Mark Stevenson in den Aufsichtsrat | DJ Qiagen beruft Mark Stevenson in den Aufsichtsrat
DOW JONES--Qiagen hat Mark Stevenson als Nachfolger von Ross Levine mit Wirkung zum vergangenen Freitag in den Aufsichtsrat berufen. Stevenson... ► Artikel lesen | |
| ERASCA | 10,610 | 0,00 % | Guggenheim More Than Doubles Erasca (ERAS) PT Following Clinical Progress and Updated Pipeline Models | ||
| RECURSION PHARMACEUTICALS | 4,175 | 0,00 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| LENZ THERAPEUTICS | 16,300 | +3,03 % | New FDA-Approved Eye Drop Sparks Fresh Competition For LENZ Therapeutics' Drug | ||
| ALUMIS | 26,420 | +7,79 % | ALUMIS INC. - S-8, Securities to be offered to employees in employee benefit plans |
XILIO THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,584 Euro und damit -1,35 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XILIO THERAPEUTICS INC finden Sie auf Wallstreet Online.